MEDICENNA THERAPEUTICS CORP (MDNA.CA) Forecast, Price Target & Analyst Ratings

TSX:MDNA • CA58490H1073

0.76 CAD

+0.01 (+1.33%)

Last: Mar 17, 2026, 07:00 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MEDICENNA THERAPEUTICS CORP (MDNA.CA).

Consensus Price Target

Price Target

CA$3.09

+ 306.56% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: Jun 23, 2026
Period: Q4 / 2026
EPS Estimate: -CA$0.05
Revenue Estimate

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

82.00%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

CA$3.09

Upside

+ 306.56%

From current price of CA$0.76 to mean target of CA$3.09, Based on 10 analyst forecasts

Low

CA$2.52

Median

CA$2.87

High

CA$4.20

Price Target Revisions

1 Month

0.00%

3 Months

-38.47%

Price Target Summary

10 Wall Street analysts provided a forecast for the next 12 months for MDNA.CA. The average price target is 3.09 CAD. This implies a price increase of 306.56% is expected in the next year compared to the current price of 0.76.

The average price target has been revised downward by 38.47% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

82.00%

MDNA.CA was analyzed by 10 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about MDNA.CA.

In the previous month the buy percentage consensus was at a similar level.

MDNA.CA was analyzed by 10 analysts. More opinions would make the average more meaningful.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2022-11-29	Guggenheim Securities	Initiate	Buy
2022-11-29	STA Research	Downgrade	Speculative Buy
2022-09-29	STA Research	Maintains	Speculative Buy
2022-09-29	HC Wainwright	Downgrade	Buy
2022-08-16	Bloom Burton	Downgrade	Buy
2022-08-16	Jones Trading	Downgrade
2022-08-10	Oppenheimer Holdings	Initiate	Buy
2022-08-10	STA Research	Reiterate	Speculative Buy
2022-07-28	Bloom Burton	Maintains	Buy
2022-06-23	STA Research	Maintains	Speculative Buy
2022-06-23	HC Wainwright	Reiterate	Buy
2022-04-13	Brookline Capital	Upgrade	Buy
2022-03-15	Maxium Group	Initiate	Buy
2021-09-22	Bloom Burton	Initiate	Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date: Jun 23, 2026
Period: Q4 / 2026
EPS Estimate: -CA$0.05
Revenue Estimate
Revenue Q2Q: N/A
EPS Q2Q: -371.98%
Number of Analysts: 5

Next Earnings Revisions

Revenue (1 Month)

N/A

Revenue (3 Months)

N/A

EPS (1 Month)

17.95%

EPS (3 Months)

17.95%

Next Earnings Summary

MDNA.CA is expected to report earnings on 6/23/2026. The consensus EPS estimate for the next earnings is -0.05 CAD and the consensus revenue estimate is 0 CAD.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031
Revenue YoY % growth											N/A	N/A	N/A 474.44%	N/A 495.53%	N/A -2.89%	N/A 55.07%
EBITDA YoY % growth	N/A	-80K	-7.42M -9,175.00%	-4.72M 36.39%	-8.23M -74.36%	-17.36M -110.94%	-22.43M -29.21%	-16.3M 27.33%	-18.67M -14.54%	-20.353M -9.01%	N/A	N/A	N/A	N/A	N/A	N/A
EBIT YoY % growth	-200K	-90K 55.00%	-7.43M -8,155.56%	-4.73M 36.34%	-8.24M -74.21%	-17.4M -111.17%	-22.47M -29.14%	-16.3M 27.46%	-18.674M -14.56%	-20.406M -9.27%	N/A -14.26%	N/A 9.04%	N/A 35.69%	N/A 354.62%	N/A -13.14%	N/A 103.39%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS YoY % growth	N/A	N/A	N/A	N/A 29.17%	-0.26 0.04%	-0.35 -34.62%	-0.42 -20.00%	-0.19 54.76%	-0.36 -89.47%	-0.15 58.33%	N/A -53.00%	N/A -95.56%	N/A -51.14%	N/A	N/A	N/A

All data in CAD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q4 / 26	Q1 / 27
EPS Q2Q % growth	-0.05 -371.98%	-0.05 15.00%
Revenue Q2Q % growth
EBITDA Q2Q % growth	N/A	N/A
EBIT Q2Q % growth	-5.942M -3.89%	N/A

All data in CAD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

-65.37%

EPS Next 5 Year

N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

N/A

Revenue Next 5 Year

N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

N/A

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

MEDICENNA THERAPEUTICS CORP / MDNA.CA Forecast FAQ

Can you provide the average price target for MEDICENNA THERAPEUTICS CORP stock?

10 analysts have analysed MDNA.CA and the average price target is 3.09 CAD. This implies a price increase of 306.56% is expected in the next year compared to the current price of 0.76.

Can you provide the upcoming earnings date for MEDICENNA THERAPEUTICS CORP?

MEDICENNA THERAPEUTICS CORP (MDNA.CA) will report earnings on 2026-06-23, after the market close.

What are the consensus estimates for MDNA stock next earnings?

The consensus EPS estimate for the next earnings of MEDICENNA THERAPEUTICS CORP (MDNA.CA) is -0.05 CAD and the consensus revenue estimate is 0 CAD.

How many analysts have analysed MEDICENNA THERAPEUTICS CORP (MDNA.CA)?

The number of analysts covering MEDICENNA THERAPEUTICS CORP (MDNA.CA) is 10.

Analyst forecast overview

Forecast Snapshot